Company Quick10K Filing
Endra Life Sciences
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 7 $-0
10-Q 2019-11-13 Quarter: 2019-09-30
10-Q 2019-08-08 Quarter: 2019-06-30
10-Q 2019-05-14 Quarter: 2019-03-31
10-K 2019-03-11 Annual: 2018-12-31
10-Q 2018-11-05 Quarter: 2018-09-30
10-Q 2018-08-13 Quarter: 2018-06-30
10-Q 2018-05-15 Quarter: 2018-03-31
10-K 2018-03-20 Annual: 2017-12-31
10-Q 2017-11-14 Quarter: 2017-09-30
10-Q 2017-08-07 Quarter: 2017-06-30
10-Q 2017-06-21 Quarter: 2017-03-31
8-K 2019-12-27 Officers, Exhibits
8-K 2019-12-19 Regulation FD, Exhibits
8-K 2019-12-19 Enter Agreement, Sale of Shares, Exhibits
8-K 2019-12-05 Enter Agreement, Sale of Shares, Regulation FD, Exhibits
8-K 2019-11-13 Earnings, Exhibits
8-K 2019-08-14
8-K 2019-07-26 Enter Agreement, Off-BS Arrangement, Sale of Shares, Regulation FD, Exhibits
8-K 2019-05-16 Shareholder Vote
8-K 2019-03-11 Earnings, Exhibits
8-K 2018-11-08 Enter Agreement, Regulation FD, Exhibits
8-K 2018-10-10 Enter Agreement, Other Events, Exhibits
8-K 2018-08-16 Delisting
8-K 2018-07-18 Regulation FD
8-K 2018-06-28 Enter Agreement, Off-BS Arrangement, Sale of Shares, Regulation FD, Exhibits
8-K 2018-06-12 Officers, Shareholder Vote, Other Events
8-K 2018-03-29
8-K 2018-03-20 Earnings, Exhibits
8-K 2018-01-30 Enter Agreement, Regulation FD, Exhibits

Endra Life Sciences Financials

NDRAU Metrics, Comps, Filings

Annual | Quarterly

Business

ENDRA Life Sciences Inc. (“ENDRA” or the “Company”) is developing a medical imaging technology based on the thermoacoustic effect that improves the sensitivity and specificity of clinical ultrasound.

On May 8, 2017, the Company effected a 1-for-3.5 reverse stock split (the “Reverse Split”) of the Company’s common stock, with no reduction in authorized capital stock. In the Reverse Split, every 3.5 outstanding shares of common stock became one (1) share of common stock. All common stock and stock incentive plan information in these financial statements reflect the Reverse Split.

ENDRA was incorporated on July 18, 2007 as a Delaware corporation.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Annual)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Inbit (INBT) 26% -0.0 27% 41 176 15 4 11 11 -1
Team 360 Sports (TSPI) 0% 0.0 -222,766% 0 190 3 0 -477 -472 -0
Embassy Bancorp (EMYB) -1.8 1% 1,134,460 1,040,868 0 0 10,358 21,830 -38,756
Kyto Technology & Life Science (KBPH) 0% 0.4 -14% 1,593 29 9 0 -230 -230 -94
Endra Life Sciences (NDRAU) 0.2 -320% 3,191 1,366 0 0 -10,197 -10,120 -2,268
Bone Biologics (BBLG) -2.6 -1,518% 266 11,122 0 0 -4,045 -4,041 10,524
1847 Holdings (EFSH) 33% 18.9 -10% 19,469 22,957 18,779 6,164 -2,004 186 3,504
ZEV Ventures (ZVVT) 76% 0.0 -802% 3,420 29,143 439 334 -27,420 -27,316 -291
KBS Growth & Income REIT (KBSGI) 0% 11.4 -4% 183,252 131,547 21,022 0 -6,938 9,859 112,573
Brownie's Marine Group (BWMG) 14% 0.1 -79% 1,885 1,704 2,477 357 -1,480 -1,478 -174
Corporate Property Associates 17 - Global (CPA17) 0% 5.9 2% 4,470,224 2,180,912 441,244 0 109,760 304,936 1,794,288
Kiewit Royalty Trust (KIRY) 0% -0.5 221% 606 750 0 1,342 1,342 -606
Quarta-Rad (QURT) 38% 1.0 -24% 299 231 626 235 -72 -72 -71
Auscrete (AUSK) 0.0 292,398,200% 916 0 0 -2,924 -3,094 -0
Atel Capital Equipment Fund IX (ZZHJC) 0% -2.8 8% 4,101 376 2,362 0 320 320 -908
RhythmOne (RHYTH) 0% 419,466 138,781 0 0 0 0 -0
Mitu Resources (MTUU) 0.0 -2,593% 2 186 0 0 -52 -50 -0
SavDen Group (SVDN) 0.0 0 142 0 0 -44 -44 -0
Phillips Edison (PHLD) 0% 7.5 0% 4,976,453 2,734,427 488,370 0 10,324 318,917 2,390,839
C&C Tours (CCT) 0.0 -9,276% 0 206 0 0 -26 -13 -0

Balance Sheet ($'000)2017-12-312018-12-31
Cash5,6026,471
Accounts Receivable70
Inventory19259
PP&E242273
Assets6,1247,223
Accounts Payable780631
Long-Term Debt
Liabilities848975
Stockholders' Equity5,2756,248
Income Statement ($'000)2017-12-312018-12-31
Revenue3526
Cost of Revenue1730
Gross Profit1796
R&D1,9314,722
SG&A2,8744,015
Tax00
Net Income-5,377-9,796
Cash Flow ($'000)2017-12-312018-12-31
Cash Operating-3,301-7,702
Cash Investing-8-100
Cash Financing8,7668,672